Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience

<div>Median overall survival for the entire cohort. Median overall survival for this cohort was 14.2 months.</div>

Case Reports in Oncological Medicine

Figure 4: Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience 